FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2076269412> ?p ?o ?g. }

• W2076269412 endingPage "1692" @default.
• W2076269412 startingPage "1684" @default.
• W2076269412 abstract "<h3>Objective:</h3> This retrospective study analyzed whether the type of radiologic progression, classified according to contrast enhancement on MRI T1-weighted sequences and changes in T2-hyperintense signal, is relevant for outcome in patients with progressive glioblastoma (pGB) treated with bevacizumab. <h3>Methods:</h3> MRI scans of 83 patients with pGB treated with bevacizumab were evaluated prior to and at disease progression. Based on initial decrease in and subsequent flare-up of contrast enhancement in T1 and 2 patterns of T2-hyperintense tumor progression, progression types (PTs) were categorized as cT1 flare-up, T2-diffuse, T2-circumscribed, or primary nonresponder. Overall survival (OS), survival from start of bevacizumab therapy (OS_Bev), survival after bevacizumab failure (OS_PostBev), time from initial diagnosis until initiation of bevacizumab therapy (StartBevT), and time to bevacizumab progression were evaluated using Kaplan-Meier curves, log-rank test, and Cox regression analyses. <h3>Results:</h3> The time observed for development of a T2-diffuse (n = 15) or a cT1 flare-up (n = 35) progression was longer than for progression in primary nonresponders (n = 16) or T2-circumscribed progression (n = 17). The T2-diffuse PT showed longer OS, OS_Bev, OS_PostBev, and StartBevT compared to the other PTs. Postprogression therapy tended to be relevant only for patients with a T2-circumscribed PT. <h3>Conclusions:</h3> Radiologic PTs following bevacizumab treatment failure show differences in time to development and are related to outcome. We therefore hypothesize that these PTs reflect a different glioma biology, including differential resistance mechanisms to bevacizumab, and may be associated with different responses to postprogression therapy." @default.
• W2076269412 created "2016-06-24" @default.
• W2076269412 creator A5005295293 @default.
• W2076269412 creator A5009020512 @default.
• W2076269412 creator A5014451875 @default.
• W2076269412 creator A5019876508 @default.
• W2076269412 creator A5039844320 @default.
• W2076269412 creator A5039985608 @default.
• W2076269412 creator A5054405140 @default.
• W2076269412 creator A5080482957 @default.
• W2076269412 creator A5084473005 @default.
• W2076269412 date "2014-04-11" @default.
• W2076269412 modified "2023-10-18" @default.
• W2076269412 title "Progression types after antiangiogenic therapy are related to outcome in recurrent glioblastoma" @default.
• W2076269412 cites W1537447319 @default.
• W2076269412 cites W1972363550 @default.
• W2076269412 cites W1992112921 @default.
• W2076269412 cites W1993016882 @default.
• W2076269412 cites W2002727873 @default.
• W2076269412 cites W2017322644 @default.
• W2076269412 cites W2023234343 @default.
• W2076269412 cites W2041617965 @default.
• W2076269412 cites W2063622451 @default.
• W2076269412 cites W2067901299 @default.
• W2076269412 cites W2090785782 @default.
• W2076269412 cites W2096123576 @default.
• W2076269412 cites W2096287682 @default.
• W2076269412 cites W2098812986 @default.
• W2076269412 cites W2099059965 @default.
• W2076269412 cites W2099391096 @default.
• W2076269412 cites W2101332957 @default.
• W2076269412 cites W2101711321 @default.
• W2076269412 cites W2102136830 @default.
• W2076269412 cites W2104317719 @default.
• W2076269412 cites W2112030606 @default.
• W2076269412 cites W2130139391 @default.
• W2076269412 cites W2131480590 @default.
• W2076269412 cites W2137261274 @default.
• W2076269412 cites W2140201170 @default.
• W2076269412 cites W2145025818 @default.
• W2076269412 cites W2156483316 @default.
• W2076269412 cites W2157500906 @default.
• W2076269412 cites W2162643152 @default.
• W2076269412 cites W2169424184 @default.
• W2076269412 cites W2170367762 @default.
• W2076269412 doi "https://doi.org/10.1212/wnl.0000000000000402" @default.
• W2076269412 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/24727314" @default.
• W2076269412 hasPublicationYear "2014" @default.
• W2076269412 type Work @default.
• W2076269412 sameAs 2076269412 @default.
• W2076269412 citedByCount "97" @default.
• W2076269412 countsByYear W20762694122014 @default.
• W2076269412 countsByYear W20762694122015 @default.
• W2076269412 countsByYear W20762694122016 @default.
• W2076269412 countsByYear W20762694122017 @default.
• W2076269412 countsByYear W20762694122018 @default.
• W2076269412 countsByYear W20762694122019 @default.
• W2076269412 countsByYear W20762694122020 @default.
• W2076269412 countsByYear W20762694122021 @default.
• W2076269412 countsByYear W20762694122022 @default.
• W2076269412 countsByYear W20762694122023 @default.
• W2076269412 crossrefType "journal-article" @default.
• W2076269412 hasAuthorship W2076269412A5005295293 @default.
• W2076269412 hasAuthorship W2076269412A5009020512 @default.
• W2076269412 hasAuthorship W2076269412A5014451875 @default.
• W2076269412 hasAuthorship W2076269412A5019876508 @default.
• W2076269412 hasAuthorship W2076269412A5039844320 @default.
• W2076269412 hasAuthorship W2076269412A5039985608 @default.
• W2076269412 hasAuthorship W2076269412A5054405140 @default.
• W2076269412 hasAuthorship W2076269412A5080482957 @default.
• W2076269412 hasAuthorship W2076269412A5084473005 @default.
• W2076269412 hasConcept C121608353 @default.
• W2076269412 hasConcept C126322002 @default.
• W2076269412 hasConcept C143998085 @default.
• W2076269412 hasConcept C2776194525 @default.
• W2076269412 hasConcept C2776694085 @default.
• W2076269412 hasConcept C2777802072 @default.
• W2076269412 hasConcept C2778227246 @default.
• W2076269412 hasConcept C2779256057 @default.
• W2076269412 hasConcept C2780739268 @default.
• W2076269412 hasConcept C3019894029 @default.
• W2076269412 hasConcept C502942594 @default.
• W2076269412 hasConcept C50382708 @default.
• W2076269412 hasConcept C71924100 @default.
• W2076269412 hasConceptScore W2076269412C121608353 @default.
• W2076269412 hasConceptScore W2076269412C126322002 @default.
• W2076269412 hasConceptScore W2076269412C143998085 @default.
• W2076269412 hasConceptScore W2076269412C2776194525 @default.
• W2076269412 hasConceptScore W2076269412C2776694085 @default.
• W2076269412 hasConceptScore W2076269412C2777802072 @default.
• W2076269412 hasConceptScore W2076269412C2778227246 @default.
• W2076269412 hasConceptScore W2076269412C2779256057 @default.
• W2076269412 hasConceptScore W2076269412C2780739268 @default.
• W2076269412 hasConceptScore W2076269412C3019894029 @default.
• W2076269412 hasConceptScore W2076269412C502942594 @default.
• W2076269412 hasConceptScore W2076269412C50382708 @default.
• W2076269412 hasConceptScore W2076269412C71924100 @default.
• W2076269412 hasIssue "19" @default.

• next